Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) have been assigned an average rating of “Moderate Buy” from the twenty-one ratings firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $251.2632.

Several research analysts have weighed in on the company. Morgan Stanley boosted their price target on Axsome Therapeutics from $217.00 to $242.00 and gave the stock an “equal weight” rating in a research report on Tuesday, May 5th. Jefferies Financial Group boosted their price target on Axsome Therapeutics from $245.00 to $275.00 and gave the stock a “buy” rating in a research report on Monday, May 4th. HC Wainwright boosted their price target on Axsome Therapeutics from $270.00 to $290.00 and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Needham & Company LLC boosted their price target on Axsome Therapeutics from $225.00 to $255.00 and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Finally, Robert W. Baird boosted their price target on Axsome Therapeutics from $241.00 to $246.00 and gave the stock an “outperform” rating in a research report on Tuesday, May 5th.

Insiders Place Their Bets

In other Axsome Therapeutics news, COO Mark L. Jacobson sold 4,517 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $227.94, for a total transaction of $1,029,604.98. Following the transaction, the chief operating officer owned 4,517 shares of the company’s stock, valued at $1,029,604.98. The trade was a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Ari Maizel sold 7,500 shares of the business’s stock in a transaction that occurred on Wednesday, April 22nd. The stock was sold at an average price of $182.42, for a total value of $1,368,150.00. Following the transaction, the insider directly owned 7,500 shares in the company, valued at $1,368,150. The trade was a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 29,787 shares of company stock valued at $6,470,391 in the last 90 days. 20.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its holdings in shares of Axsome Therapeutics by 6.0% during the 3rd quarter. Vanguard Group Inc. now owns 4,180,646 shares of the company’s stock worth $507,739,000 after acquiring an additional 235,626 shares during the last quarter. Franklin Street Advisors Inc. NC acquired a new position in shares of Axsome Therapeutics during the 4th quarter worth approximately $1,826,000. Aberdeen Group plc increased its holdings in shares of Axsome Therapeutics by 15.5% during the 3rd quarter. Aberdeen Group plc now owns 94,648 shares of the company’s stock worth $11,495,000 after acquiring an additional 12,732 shares during the last quarter. TD Asset Management Inc increased its holdings in shares of Axsome Therapeutics by 107.7% during the 3rd quarter. TD Asset Management Inc now owns 44,192 shares of the company’s stock worth $5,367,000 after acquiring an additional 22,914 shares during the last quarter. Finally, Pictet Asset Management Holding SA increased its holdings in shares of Axsome Therapeutics by 20.4% during the 4th quarter. Pictet Asset Management Holding SA now owns 436,063 shares of the company’s stock worth $79,643,000 after acquiring an additional 73,925 shares during the last quarter. 81.49% of the stock is owned by institutional investors and hedge funds.

Axsome Therapeutics Trading Up 5.0%

NASDAQ AXSM opened at $233.31 on Friday. The stock has a market capitalization of $12.01 billion, a price-to-earnings ratio of -62.55 and a beta of 0.61. The stock’s 50 day moving average price is $199.79 and its two-hundred day moving average price is $177.40. The company has a debt-to-equity ratio of 2.27, a quick ratio of 1.32 and a current ratio of 1.39. Axsome Therapeutics has a 52 week low of $96.09 and a 52 week high of $238.56.

Axsome Therapeutics (NASDAQ:AXSM) last released its earnings results on Monday, May 4th. The company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.41). The firm had revenue of $191.20 million during the quarter, compared to the consensus estimate of $191.10 million. Axsome Therapeutics had a negative net margin of 26.59% and a negative return on equity of 267.16%. The business’s revenue for the quarter was up 57.4% on a year-over-year basis. As a group, analysts anticipate that Axsome Therapeutics will post -2.14 earnings per share for the current fiscal year.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.